Hikal Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/4bukikfvddp19u1mplcpe4g3.pdf

Key Takeaways


Margin Recovery Path

Sameer Hiremath: "From H2 FY24 onwards, we'll start moving towards the FY22 margins exit run rate. And after that, from FY25 onwards, we expect this sequential growth to come back. I think there's a little bit of pause for 1.5 years because of market conditions and external environment, but the medium to long-term perspective, we are still at confident goal."

Animal Health: The Next Growth Engine

Anish Swadi: "We'll commercialize the plant in the end of Q2... We'll supply validation batches of all the products that we have over the next 14 months to 18 months, which is basically till the end of next financial year. And then we'll start full commercial production. So we will generate revenue and profits in the next 14 months to 18 months, and then the commercial quantities will start, whereby we will generate higher revenues and higher profits."

Pharma: Pricing Stabilization & Portfolio Shift

Manoj Mehrotra: "Any DMF, which we file, there will be a replication of at least 10 to 15 DMFs of the same product. So the only way to stay ahead of the competition, it really be a little early for launch, number one. And number two, always be ahead in the cost curve... And if you really don't have any competitive advantage, you tend to fall in the trap of price reduction."

Crop Protection: Near-Term Pain, CDMO Traction


Capex Cycle Nearing Completion


China Plus One: Structural Tailwind

Sameer Hiremath: "I think the decisions have already been made. And customers are not looking at just as a short-term impact. They are looking at it more from a long-term perspective... all is not going to move to India, but even if a fraction of what the China moves to India, is going to keep all the top Indian companies busy for several years to come."

Guidance & Commitments

CommitmentSpecificsTimeline
Channel inventory normalizationHigher than normal inventory levels with customers expected to easeTowards end of Q2 FY24
Animal Health plant commercializationPlant operational, validation batches supplied over next 14–18 months, then full commercial productionEnd of Q2 FY24
Crop Protection multipurpose plant commissioningPlant in stabilization phase, commissioning progressing as plannedNext few months (Q2 FY24)
API product launches3–4 products launched from pipeline of 8–10 under developmentBy end of FY24
Full-year FY24 marginsMargins not contract to slightly expand vs FY23; FY24 EBITDA better than FY23 EBITDAFY24
H2 FY24 margin trajectoryH2 margins far better than H1; Q4 FY24 margins better than Q4 FY23H2 FY24
Margin run-rate recoveryStart moving towards FY22 margins exit run rateFrom H2 FY24 onwards
Sequential growth returnSequential growth expected to come back once new capacities start kicking inFrom FY25 onwards
Animal Health peak utilizationReach peak optimization2.5 to 3 years from start
CapexNo new major capex; only maintenance and small debottleneckingFY24

Key Metrics

MetricQ4 FY23
Revenue₹545 cr, +8.5% YoY
Full-year revenue₹2,023 cr, +4% YoY
EBITDA (full year)₹257 cr, vs ₹341 cr in FY22
Profit after tax₹36 cr (Q4), ₹78 cr (full year)
Pharma revenue₹309 cr, +0.3% YoY
Pharma EBIT margin11.7%, EBIT of ₹36 cr
Crop Protection revenue₹236 cr, +22% YoY
Crop Protection EBIT margin11.4%, EBIT of ₹31 cr, +167% YoY
Debt-to-equity ratio0.61x, vs 0.59x in FY22
Dividend per share (FY23)₹1.20, 60% of face value
Pharma volume growth+10% YoY
Crop Protection volume growth-13% YoY
Pharma CDMO vs own products mix~50-50, varies quarter-to-quarter
R&D spend~4% of revenue, 3.5%–4% range
DMF filings (FY23)3 filed, plan for 3–4 annually
Capex (last 3 years)₹700 cr
Capex (FY24 estimate)₹200 cr
Animal Health commercial timeline~1 year 9 months from May 2023 to full commercial supplies